-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Acrivon Therapeutics, Maintains $13 Price Target

Benzinga·11/17/2026 14:19:16
Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.